Increased levels of circulating platelet derived microparticles in Crohn's disease patients

Objective: Platelet activation is a consistent feature in inflammatory bowel disease. However, the role of circulating platelet derived microparticles (PDMPs) and the effects of disease activity and treatment on their levels has not been clarified yet in this disorder.

Material and methods: Using flow cytometry, we measured platelet derived microparticles and platelet derived microparticles expressing Annexin V in platelet rich plasma from 47 Crohn’s disease and 43 ulcerative colitis patients and 24 healthy controls.

Results: Crohn’s disease patients have greater PDMPs (0.31% ± 0.07% versus 0.14% ± 0.04%, p?=?0.02) and PDMPs expressing Annexin V (27% ± 2.6% versus 14.6% ± 2.7%, p?=?0.002) levels in comparison with healthy controls; however, both microparticles levels are not related with disease activity. Crohn’s disease patients on 5-ASA therapy show lower levels of PDMPs in comparison with those on no 5-ASA (0.30% ± 0.07% versus 0.32% ± 0.09%, p?=?0.048). Ulcerative colitis patients have similar PDMPs and PDMPs expressing Annexin V levels, compared to healthy controls (p?=?0.06 and p?=?0.2, respectively) and there is no correlation of both microparticles expression with disease activity. 5-ASA has no effect on both microparticles levels in ulcerative colitis patients. Anti-TNF-α treatment has no effect on study’s microparticles expression in Crohn’s and ulcerative colitis patients.

Conclusions: Circulating levels of platelet derived microparticles are increased only in Crohn’s patients, but they do not correlate with disease activity. 5-ASA treatment is associated with lower levels of PDMPs only in Crohn’s, while anti-TNF-α treatment does not influence expression of microparticles in inflammatory bowel disease patients.